BC Platforms, Euformatics and Oncompass Drugs type a partnership to develop oncology NGS workflows for purchaser consortium of seven main European hospitals

ZURICH, Might 18, 2022 /PRNewswire/ — BC Platforms (BCP), a world chief in healthcare information administration and analytics, Euformatics, headquartered in Finlandand Oncompass Drugs, headquartered in Hungaryhave shaped a partnership to bid for the event of standardized oncology workflows for a purchaser consortium of seven main hospitals* primarily based in Central Europe and co-funded by the European Union Grant Settlement quantity 874719. The customer consortium, represented by the Medical College Graz, evaluated all proposals, and awarded a contract to the consortium of BC Platforms, Euformatics and Oncompass Drugs.

Instand-NGS4P is a H2020 funded undertaking for enhancing most cancers sufferers’ profit from Subsequent Era Sequencing (NGS) by creating an built-in and standardized NGS workflow and integrating data from most cancers gene testing, pharmacogenetics testing and e-medication in correct presentation to medical medical doctors help remedy choice at bedside. The undertaking began in Jan 2020 and has now developed to a degree the place suppliers for design of the standardized NGS workflows have been chosen after an open market session and name for tenders. This system will run till Might 2025 with a complete pre-commercial procurement price range of roughly 8 million euros.

Through the open market session in 2021 BC Platforms, Euformatics and Oncompass Drugs determined to hitch forces and reply to the tender collectively to leverage the strengths of every associate and construct a robust proposal. The mix of current IP and experience in areas corresponding to genomic information administration, variant interpretation, NGS information high quality management and precision oncology satisfied the evaluators to award contracts to the partnership in each post-sequencing technical modules, specifically bioinformatic evaluation and built-in reporting.

Kurt ZatloukalProfessor of Pathology on the Medical College Graz feedback: “Pushed by affected person and medical wants, progressive NGS workflows from sample-pre-analytics to medical choice making shall be developed in this system by the main European SMEs on this area. The joint proposal by BC Platforms, Euformatics and Oncompass Drugs was evaluated by main specialists and chosen for funding. We glance very a lot ahead to a stimulating collaboration and a profitable undertaking.”

The provider aspect of this contract is equally excited in regards to the collaboration forward.

Tero SilvolaCEO of BC Platforms, feedback on the partnership and awarded contract: “We knew early on that this program gives the chance to outline the medical practices for oncology and precision medication for years to return if we achieve being a part of it. We’ve got the genomic information administration platform on high of which the workflows could be designed . We’ve got a protracted historical past of working with Euformatics so partnering with them for variant interpretation and high quality management was pure and Oncompass Drugs contributes strongly for the e-medication a part of this system.”

Tommi KaasalainenCEO of Euformatics, continues: “Instand-NGS4P program hits the candy spot from our product growth and experience perspective. That is actually a win-win since we will construct on high of the prevailing omnomicsSUITE product household in shut collaboration with main European healthcare establishments. Having deployed a number of medical options along with BC Platforms in NorthAmerica, Europe different Asia, I’m assured that the partnership will work properly. Oncompass Drugs is a really welcome addition to the consortium, offering worth past our capabilities.”

Prof. Dr. Istvan PetakFounder and CEO of Oncompass Drugs, concludes: “Our breakthrough AI-powered oncology software program may also help oncologists discover the best focused remedy for each most cancers affected person primarily based on the entire complicated molecular profile of their tumor. This being the final step within the NGS workflow we needed to associate with BC Platforms and Euformatics to cowl the total post-sequencing bioinformatics and reporting with an built-in end-to-end resolution that shall be straightforward for the hospitals to deploy after the undertaking is accomplished. Trying ahead to pushing the envelope.”

The primary section of the undertaking begins instantly and the outcomes of the primary section shall be delivered in mid Aug 2022. The buying consortium will then consider the output of all section 1 contractors and choose the very best ones to proceed to section 2. Equally after the second section there shall be a aggressive choice to award the ultimate third section contracts to ultimately deploy and combine in 2025 two standardized NGS workflows as the results of the Instand-NGS4P program.

*The consortium is shaped by hospitals from the Medical College of Graz in AustriaCollege of Florence and College of Milano-Bicocca in Italy, Erasmus College Medical heart in the NetherlandsChristian-Albrecht College of Kiel and St. Anna Youngsters’s Most cancers Analysis Institute in Germanyand the Middle Léon Bérard in France.

About Instand-NGS4P:

Instand-NGS4P is a 65-month PCP undertaking federating 7 main medical facilities (two are coordinating ERNs) as patrons’ teams with main expertise in utilizing totally different NGS platforms in analysis and routine diagnostics. The consortium is additional strengthened by European affected person advocacy teams, a standardization group and companions collaborating within the European infrastructures BBMRI-ERIC, ELIXIR in addition to a number of NGS-related EU packages to cowl all technical elements and transversal wants & necessities.

For extra data, please go to the web site www.maintenance4p.eu

About BC Platforms:

BC Platforms is a world chief in offering a strong information and know-how platform for customized medication and drug growth, accelerating the interpretation of insights into medical follow. Our know-how drives the infinite loop between customized care and analysis discoveries, leveraging newest science, deep technical experience, strategic partnerships, and harmonized, numerous information collections. Our excessive performing genomic information discovery and analytics platform allows versatile information integration, safe evaluation and interpretation of molecular and medical data.

For extra data, please go to the web site www.bcplatforms.com

About Euformatics:

Euformatics is a Finnish software program firm that focuses on excessive commonplace bioinformatics instruments for genomic information interpretation. Since 2010, Euformatics has been serving to medical medical doctors, molecular genetics and pathology laboratories, and EQA suppliers to ship most correct outcomes for the advantage of sufferers. Our current core resolution is omnomicsSUITE, which incorporates omnomicsNGS for variant calling, annotation, classification, and reporting, and omnomicsQ for NGS information high quality administration and NGS-based take a look at validation and verification.

For extra data, please go to the web site www.euformatics.com

About Oncompass Drugs:

Oncompass is the winner of the Future Unicorn Award 2021 of DIGITALEUROPE, the affiliation of know-how corporations in forty international locations in Europe. The corporate is the worldwide champion of GETINTHERING startup competitors 2021 out of competing corporations of 109 international locations. Oncompass was the primary to develop a software program as a medical gadget primarily based on synthetic intelligence that proved to enhance therapeutic choices in precision oncology. Oncompass additionally gives end-to-end providers for oncology facilities that want to present precision oncology to their sufferers.

For extra data, please go to the web site www.oncompassmedicine.com


surgical procedure

View unique content material:https://www.prnewswire.com/news-releases/bc-platforms-euformatics-and-oncompass-medicine-form-a-partnership-to-develop-oncology-ngs-workflows-for-buyer-consortium-of- seven-major-european-hospitals-301549474.html

SOURCE BC Platforms

Leave a Comment